Alphatec (NASDAQ:ATEC) Upgraded by Wall Street Zen to Buy Rating

Key Points

• Alphatec (NASDAQ: ATEC) has been upgraded from a "hold" to a "buy" rating by Wall Street Zen, with seven analysts now rating the stock as a Buy.
• In its latest earnings report, Alphatec reported earnings per share of $0.02, surpassing estimates and showing a 27.5% year-over-year increase in revenue.
• The company's stock has a current consensus target price of $18.14 and recently traded at $14.89, reflecting ongoing investor interest.

Alphatec (NASDAQ:ATEC - Get Free Report) was upgraded by analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a report released on Saturday.

Other research analysts also recently issued research reports about the company. Barclays reiterated an "overweight" rating and set a $22.00 price target (up previously from $21.00) on shares of Alphatec in a research note on Monday, August 4th. Wells Fargo & Company increased their price target on Alphatec from $14.00 to $16.00 and gave the stock an "overweight" rating in a research note on Thursday. Weiss Ratings reiterated a "sell (d-)" rating on shares of Alphatec in a research note on Tuesday. Finally, Canaccord Genuity Group reiterated a "buy" rating and set a $20.00 price target on shares of Alphatec in a research note on Friday, August 1st. Seven equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Alphatec presently has an average rating of "Moderate Buy" and a consensus target price of $18.14.

Alphatec Trading Up 4.4%

Shares of Alphatec stock opened at $14.89 on Friday. Alphatec has a 1 year low of $5.08 and a 1 year high of $16.70. The firm has a market cap of $2.20 billion, a PE ratio of -13.18 and a beta of 1.05. The stock has a fifty day moving average price of $15.16 and a 200-day moving average price of $12.78. The company has a debt-to-equity ratio of 23.22, a current ratio of 2.88 and a quick ratio of 1.77.

Alphatec (NASDAQ:ATEC - Get Free Report) last announced its earnings results on Thursday, July 31st. The medical technology company reported $0.02 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.08. The business had revenue of $185.54 million for the quarter, compared to analysts' expectations of $178.85 million. During the same period in the prior year, the business earned ($0.29) earnings per share. The company's revenue for the quarter was up 27.5% compared to the same quarter last year. Alphatec has set its FY 2025 guidance at EPS. Equities research analysts anticipate that Alphatec will post -1.08 EPS for the current year.

Insiders Place Their Bets

In other Alphatec news, EVP Craig E. Hunsaker sold 50,000 shares of the firm's stock in a transaction dated Tuesday, August 5th. The stock was sold at an average price of $15.00, for a total value of $750,000.00. Following the completion of the transaction, the executive vice president owned 1,400,018 shares in the company, valued at $21,000,270. This trade represents a 3.45% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Patrick Miles sold 300,000 shares of the firm's stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $15.73, for a total value of $4,719,000.00. Following the completion of the transaction, the chief executive officer owned 5,564,078 shares of the company's stock, valued at approximately $87,522,946.94. This represents a 5.12% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 780,575 shares of company stock worth $11,769,527 over the last quarter. Insiders own 20.90% of the company's stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in ATEC. GAMMA Investing LLC boosted its stake in Alphatec by 38,433.3% in the 1st quarter. GAMMA Investing LLC now owns 2,312 shares of the medical technology company's stock worth $228,000 after purchasing an additional 2,306 shares during the period. SG Americas Securities LLC boosted its position in shares of Alphatec by 28.3% during the 1st quarter. SG Americas Securities LLC now owns 56,927 shares of the medical technology company's stock valued at $577,000 after acquiring an additional 12,553 shares during the last quarter. Wealth Enhancement Advisory Services LLC boosted its position in shares of Alphatec by 301.0% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 59,987 shares of the medical technology company's stock valued at $608,000 after acquiring an additional 45,027 shares during the last quarter. Segment Wealth Management LLC bought a new stake in shares of Alphatec during the 1st quarter valued at about $101,000. Finally, Oppenheimer Asset Management Inc. boosted its position in shares of Alphatec by 13.4% during the 1st quarter. Oppenheimer Asset Management Inc. now owns 13,144 shares of the medical technology company's stock valued at $133,000 after acquiring an additional 1,552 shares during the last quarter. Institutional investors own 66.35% of the company's stock.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.